Session

Overview: In this fierce debate, experienced colleagues will explain us whether the level-1 evidence demonstrated effects of regional nodal irradiation (RNI) in decreasing relapses and improving survival for breast cancer patients continue outweighing possible late toxicity in the present era of more effective systemic therapies. We will be asked how we can identify the specific internal mammary (IM) irradiation benefit as component of RNI? What is the impact of more individualised RNI techniques, on both efficacy and toxicity, especially in view of contemporary systemic agents? How can we fit individualisation of indications, prescriptions, and techniques in the ongoing trend of decreasing surgical extent? So, let you take away by the debaters, absorb and process all information and finally decide and vote for yourself whether you agree or not with the statement that IM irradiation should be standard of care for high-risk breast cancer patients!